Ascelia touts MRI contrast agent study

By staff writers

December 19, 2022 -- Ascelia Pharma is highlighting results from a study presented at the RSNA meeting in Chicago that shows the effect of food intake on the absorption and signal intensity of its manganese-based MRI contrast agent for liver indications, Orviglance.

The research included 24 participants, some of whom fasted before having an MRI exam and others who had a light or full meal. It demonstrated that image enhancement with the agent is not affected by a patient having a light meal before undergoing MRI, the company said.

Ascelia plans to include this data in a new drug application (NDA) it will submit to the U.S. Food and Drug Administration (FDA). The FDA has granted Orviglance Orphan Drug Designation, according to the firm.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking